` ALEC (Alector Inc) vs S&P 500 Comparison - Alpha Spread

ALEC
vs
S&P 500

Over the past 12 months, ALEC has underperformed S&P 500, delivering a return of -77% compared to the S&P 500's 12% growth.

Stocks Performance
ALEC vs S&P 500

Loading
ALEC
S&P 500
Add Stock

Performance Gap
ALEC vs S&P 500

Loading
ALEC
S&P 500
Difference

Performance By Year
ALEC vs S&P 500

Loading
ALEC
S&P 500
Add Stock

Competitors Performance
Alector Inc vs Peers

S&P 500
ALEC
ABBV
AMGN
GILD
VRTX
Add Stock

Alector Inc
Glance View

Market Cap
120.9m USD
Industry
Biotechnology

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

ALEC Intrinsic Value
6.3 USD
Undervaluation 81%
Intrinsic Value
Price
Back to Top